LEUKEMIA & LYMPHOMA

Scope & Guideline

Leading the charge in leukemia and lymphoma insights.

Introduction

Welcome to your portal for understanding LEUKEMIA & LYMPHOMA, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1042-8194
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1989 to 2024
AbbreviationLEUKEMIA LYMPHOMA / Leuk. Lymphoma
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'LEUKEMIA & LYMPHOMA' is dedicated to advancing the understanding and treatment of hematologic malignancies, particularly leukemia and lymphoma. It publishes original research, reviews, and clinical studies that encompass various aspects of these diseases, including their biology, diagnosis, treatment, and management.
  1. Clinical Research and Trials:
    Focuses on clinical studies evaluating new therapies, treatment regimens, and outcomes for patients with leukemia and lymphoma, contributing to evidence-based medical practices.
  2. Molecular and Genetic Insights:
    Explores the genetic and molecular underpinnings of hematologic malignancies, including mutations, gene expressions, and their implications for treatment and prognosis.
  3. Patient-Centered Outcomes:
    Investigates the quality of life, treatment adherence, and psychological aspects affecting patients with hematologic cancers, emphasizing the importance of holistic patient care.
  4. Epidemiology and Public Health:
    Analyzes the incidence, prevalence, and demographic factors related to leukemia and lymphoma, providing insights into public health strategies and healthcare resource allocation.
  5. Innovative Therapeutic Approaches:
    Covers cutting-edge treatments, including targeted therapies, immunotherapies, and novel drug combinations, aimed at improving patient outcomes.
The journal 'LEUKEMIA & LYMPHOMA' has increasingly focused on several trending and emerging themes that reflect the dynamic landscape of hematologic research and clinical practice. These themes are indicative of technological advancements and changing paradigms in treatment and diagnosis.
  1. Targeted and Precision Medicine:
    There is a growing emphasis on research exploring targeted therapies and precision medicine approaches tailored to the genetic profiles of individual patients, particularly in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
  2. Immunotherapy Developments:
    Research on immunotherapeutic strategies, including CAR T-cell therapies and immune checkpoint inhibitors, is trending, showcasing their transformative impact on treatment outcomes for various hematologic malignancies.
  3. Real-World Evidence Studies:
    An increasing number of studies are focusing on real-world evidence to assess treatment effectiveness, patient adherence, and healthcare resource utilization, providing insights that complement clinical trial data.
  4. Biomarker Discovery and Application:
    The identification and utilization of biomarkers for diagnosis, prognosis, and treatment response are emerging as critical areas of study, helping to guide personalized treatment strategies.
  5. Health Economics and Patient-Reported Outcomes:
    There is a rising interest in health economics related to treatment costs, patient-reported outcomes, and quality of life assessments in the management of hematologic malignancies.

Declining or Waning

While 'LEUKEMIA & LYMPHOMA' continues to evolve with emerging research areas, certain themes have seen a decline in focus over recent years. This shift may reflect changes in research priorities, funding, and clinical practice.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in studies solely focused on conventional chemotherapy protocols, as research increasingly emphasizes targeted therapies and personalized medicine.
  2. Longitudinal Studies of Older Treatment Protocols:
    Research examining older treatment protocols for leukemia and lymphoma appears to have waned, possibly due to the rapid advancement of newer, more effective therapies.
  3. Single-Agent Studies:
    The trend towards evaluating single-agent therapies is diminishing, as combination therapies demonstrating synergistic effects are becoming more prevalent in research.
  4. Pathology-Based Classification Systems:
    Interest in solely histopathological classifications is declining, with a shift towards molecular and genetic classifications that provide more nuanced prognostic and therapeutic insights.
  5. Invasive Diagnostic Techniques:
    There has been a shift away from invasive diagnostic methods, such as bone marrow biopsies, towards less invasive and more comprehensive approaches, including liquid biopsies.

Similar Journals

ANNALS OF HEMATOLOGY

Empowering the scientific community with quality contributions.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Navigating the Future of Blood Health Research
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Cancer Discovery

Bridging Discovery and Treatment in Cancer Care
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

Blood Cancer Discovery

Uncovering Breakthroughs in Blood Cancer Science
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Blood Advances

Elevating Hematology Through Cutting-Edge Research
Publisher: ELSEVIERISSN: 2473-9529Frequency: 24 issues/year

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

CURRENT OPINION IN HEMATOLOGY

Exploring the forefront of hematology research and insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

Indian Journal of Hematology and Blood Transfusion

Transforming Blood Health: Where Research Meets Practice
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Enhancing understanding, improving outcomes for young patients.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Experimental Hematology & Oncology

Empowering Discovery in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

BLOOD

Connecting Scholars, Advancing Knowledge in Blood Research.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.